Treatment(s) already received-Chemotherapy - Page 15 of 16 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Chemotherapy Posts on Medivizor

Panitumumab combined with irinotecan as a treatment for metastatic colorecatal cancer without KRAS mutations

Panitumumab combined with irinotecan as a treatment for metastatic colorecatal cancer without KRAS mutations

Posted by on Apr 7, 2013 in Colorectal cancer | 0 comments

In a nutshell This study looks at the use of panitumumab and irinotecan as a combination treatment in patients with KRAS wild-type (non-mutated) metastatic colorectal cancer which has continued to progress while on standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan, bevacizumab).   Some background Cancer cells can have...

Read More

Evaluating relapse patterns in stage III melanoma patients

Evaluating relapse patterns in stage III melanoma patients

Posted by on Mar 30, 2013 in Melanoma | 0 comments

In a nutshell The present article evaluated the time interval and site of relapse (return of the cancer) as well as survival rates in stage III melanoma patients who were considered cured after treatment.  Some background Stage III melanoma is skin cancer that has spread to the nearby lymph nodes. Further classification (III A, III B and III...

Read More

Addition of Aflibercept to FOLFIRI improves survival rates in patients previously treated with Oxaliplatin

Addition of Aflibercept to FOLFIRI improves survival rates in patients previously treated with Oxaliplatin

Posted by on Mar 24, 2013 in Colorectal cancer | 0 comments

In a nutshell This study investigated the use of the chemotherapy regimen known as FOLFIRI with or without the addition of Aflibercept (Zaltrap) to treat metastatic colorectal cancer.  Results showed that adding Aflibercept significantly increased the length of time patients survive and the length of time they survive without any disease...

Read More

Postoperative lymph node radiotherapy versus observation for melanoma patients with a high risk of cancer relapse

Posted by on Mar 24, 2013 in Melanoma | 0 comments

In a nutshell The present article evaluated the benefits of adjuvant radiotherapy (RT) compared to observation alone after therapeutic lymphadenectomy (TL) for melanoma patients with a high risk of lymph node relapse (return of cancer to the lymph nodes). Some background Patients with a history of melanoma are at increased risk of developing...

Read More

Operative versus non-operative treatment for recurrent rectal cancer: impact on long-term survival

Operative versus non-operative treatment for recurrent rectal cancer: impact on long-term survival

Posted by on Mar 12, 2013 in Colorectal cancer | 0 comments

In a nutshell The present paper compares long-term survival rates of surgery versus non-operative treatments in patients with recurrent rectal cancer (RRC). Some background Rectal cancer is cancer in the final section of the large intestine, or rectum. Surgery to remove the cancer is the first choice of treatment, but chemotherapy with or...

Read More

Bosutinib: a new drug that increases progression free survival in patients with locally advanced or metastatic breast cancer

Bosutinib: a new drug that increases progression free survival in patients with locally advanced or metastatic breast cancer

Posted by on Mar 11, 2013 in Breast cancer | 0 comments

In a nutshell This paper presents the results of a clinical study which looked at the use of a new drug called Bosutinib (Bosulif) for the treatment of breast cancers diagnosed as being stage III or IV. In patients previously treated with chemotherapy, Bosutinib showed promising efficacy in delaying cancer progression. Some background Locally...

Read More

The association between insulin blood levels and risk of death in breast cancer patients

Posted by on Feb 28, 2013 in Breast cancer | 0 comments

In a nutshell The present study evaluated the relationship between high insulin levels in the blood stream and the risk of cancer-related mortality. Its authors report that women with higher-than-normal insulin levels are at higher risk of death due to breast cancer. Some background Breast cancer has been shown to be more common in people who...

Read More

Combining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation

Combining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation

Posted by on Feb 25, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated whether combining Bevacizumab (Avastin) with chemotherapy for patients with stage IV (metastatic) colorectal cancer (CRC) has any benefits in the terms of survival and quality of life. Main findings: Bevacizumab may be beneficial only as part of certain chemotherapy regimens. Some...

Read More